Changes to diabetes therapy access on the Pharmaceutical Benefits Scheme: ensuring equitable access.

Intern Med J

Department of Endocrinology and Diabetes, Western Health, Melbourne, Victoria, Australia.

Published: December 2024

Download full-text PDF

Source
http://dx.doi.org/10.1111/imj.16578DOI Listing

Publication Analysis

Top Keywords

changes diabetes
4
diabetes therapy
4
therapy access
4
access pharmaceutical
4
pharmaceutical benefits
4
benefits scheme
4
scheme ensuring
4
ensuring equitable
4
equitable access
4
access
2

Similar Publications

Efficient and accurate nanocarrier development for targeted drug delivery is hindered by a lack of methods to analyze its cell-level biodistribution across whole organisms. Here we present Single Cell Precision Nanocarrier Identification (SCP-Nano), an integrated experimental and deep learning pipeline to comprehensively quantify the targeting of nanocarriers throughout the whole mouse body at single-cell resolution. SCP-Nano reveals the tissue distribution patterns of lipid nanoparticles (LNPs) after different injection routes at doses as low as 0.

View Article and Find Full Text PDF

Chinese Visceral Adiposity Index Trajectory and Stroke in Prediabetes and Diabetes: A Prospective Cohort Study.

Diabetes Metab Res Rev

January 2025

Key Laboratory of Environmental Stress and Chronic Disease Control & Prevention, Department of Biostatistics and Epidemiology, Ministry of Education, School of Public Health, China Medical University, Shenyang, China.

Aims: Stroke is a common diabetic complication, by which the Chinese visceral adiposity index (CVAI) is confirmed as a better predictor of visceral fat. However, the relationship between CVAI change and the stroke risk among patients with diabetes and prediabetes remains unclear. Therefore, we aimed to examine the association of CVAI trajectory with the risk of stroke.

View Article and Find Full Text PDF

This study evaluates the effects of liraglutide on albuminuria, oxidative stress, and inflammation in type 2 diabetes (T2D) patients with different urinary albumin-to-creatinine ratio (UACR) categories. We enrolled 107 patients with T2D who were initiating liraglutide for glycemic control. Patients were categorized into 3 groups: group I (UACR < 30 mg/g); group II (30 mg/g ≤ UACR ≤ 300 mg/g); group III (UACR > 300 mg/g).

View Article and Find Full Text PDF

The objectives of the study were to: 1) Describe characteristics and lifestyle factors of individuals who have achieved type 2 diabetes (T2D) remission (sub-diabetes glucose levels without glucose-lowering medications for ≥3 months) through changes to diet and exercise behaviour in real-world settings; 2) Investigate continuous glucose monitoring (CGM) profiles of these individuals and explore how dietary pattern may influence glucose regulation metrics. This cross-sectional study recruited individuals living with T2D who achieved remission via changes to diet or exercise behaviours. Various questionnaires were used to assess overall health and participants wore a blinded CGM for 14 days to assess glucose profiles and filled out three-day food records.

View Article and Find Full Text PDF

Background: Nephrology has seen an uptake in transition to remote care delivery. The impact of telenephrology care on chronic kidney disease (CKD) progression is not well defined.

Methods: We analyzed data from patients naturally selected for telenephrology versus standard, in-person visits.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!